Active Ingredient History
Lacosamide is an anticonvulsant that is FDA approved for the treatment of partial-onset seizures. The precise mechanism by which lacosamide exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing Common adverse reactions include diplopia, headache, dizziness, nausea. Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to Lacosamide tablets. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Alcoholism (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anxiety Disorders (Phase 3)
Arthritis, Rheumatoid (Phase 2)
Brain Neoplasms (Phase 2)
Chronic Pain (Phase 2)
Dementia (Phase 3)
Depression (Phase 3)
Diabetic Neuropathies (Phase 3)
Drug Resistant Epilepsy (Phase 4)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Fibromyalgia (Phase 2)
Glioma (Phase 4)
Healthy Volunteers (Phase 1)
Kidney Failure, Chronic (Phase 1)
Migraine Disorders (Phase 2)
Neuralgia (Phase 2)
Neuralgia, Postherpetic (Phase 2)
Osteoarthritis (Phase 2)
Pain (Phase 2)
Peripheral Nerve Injuries (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Pharmacokinetics (Phase 4)
Psychophysiologic Disorders (Phase 3)
Renal Insufficiency (Phase 4)
Schizophrenia (Phase 3)
Seizures ()
Small Fiber Neuropathy (Phase 3)
Status Epilepticus (Phase 3)
Vascular Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
